Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BioReliance acquires Big Blue assay colonies from Sigma-Aldrich
April 2013
SHARING OPTIONS:

ST. LOUIS—Sigma-Aldrich Corp. has announced that BioReliance, the biologics and early development services business under SAFC, has signed an agreement with Agilent Technologies to acquire the necessary colonies for the Big Blue transgenic rodent mutation assay and a license to the associated trademark. BioReliance originally validated the Big Blue Testing Array for use as a GLP regulatory submission assay to detect chromosomal and/or gene mutation together with Agilent.
 
"It is often of critical importance to use an in-vivo mutation assay in order to assess human risk in drug development and chemical manufacturing … we believe there will be an ever-increasing demand for transgenic rodent assays and we are delighted to be able to bring that capability to customers on the back of this agreement," said Daniel Aparicio, executive director and general manager of Early Development Services at BioReliance.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.